Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer

M. Sarfaty; P. S. Hall; K. K.W. Chan; K. Virik; M. Leshno; N. Gordon; A. Moore; V. Neiman; E. Rosenbaum; D. A. Goldstein

doi:10.1097/01.JU.0000585768.72427.cb

Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer

M. Sarfaty, P. S. Hall, K. K.W. Chan, K. Virik, M. Leshno, N. Gordon, A. Moore, V. Neiman, E. Rosenbaum, D. A. Goldstein

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1095
Number of pages	1
Journal	Journal of Urology
Volume	202
Issue number	6
DOIs	https://doi.org/10.1097/01.JU.0000585768.72427.cb
State	Published - 1 Dec 2019
Externally published	Yes

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/01.JU.0000585768.72427.cb

Cite this

@article{5811eaf9b3f94eea83d8d69c7a23f62e,

title = "Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer",

author = "M. Sarfaty and Hall, {P. S.} and Chan, {K. K.W.} and K. Virik and M. Leshno and N. Gordon and A. Moore and V. Neiman and E. Rosenbaum and Goldstein, {D. A.}",

year = "2019",

month = dec,

day = "1",

doi = "10.1097/01.JU.0000585768.72427.cb",

language = "English",

volume = "202",

pages = "1095",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Re

T2 - Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer

AU - Sarfaty, M.

AU - Hall, P. S.

AU - Chan, K. K.W.

AU - Virik, K.

AU - Leshno, M.

AU - Gordon, N.

AU - Moore, A.

AU - Neiman, V.

AU - Rosenbaum, E.

AU - Goldstein, D. A.

PY - 2019/12/1

Y1 - 2019/12/1

UR - http://www.scopus.com/inward/record.url?scp=85085072394&partnerID=8YFLogxK

U2 - 10.1097/01.JU.0000585768.72427.cb

DO - 10.1097/01.JU.0000585768.72427.cb

M3 - Comment/debate

C2 - 31532283

AN - SCOPUS:85085072394

SN - 0022-5347

VL - 202

SP - 1095

JO - Journal of Urology

JF - Journal of Urology

IS - 6

ER -

Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this